Delta-Fly Pharma
4598.TTSE GROWTHPharmaceutical
Filed as Delta-Fly Pharma,Inc. (2022-06–2026-06)
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Operating income | −¥1.6bn | −¥1.7bn | −¥1.4bn | −¥1.3bn | −¥961m | −¥852m |
| Ordinary income | −¥1.6bn | −¥1.7bn | −¥1.4bn | −¥1.3bn | −¥964m | −¥859m |
| Total assets | ¥247m | ¥434m | ¥1.5bn | ¥907m | ¥1.3bn | ¥2.2bn |
| Net assets / equity | ¥34m | ¥278m | ¥1.2bn | ¥791m | ¥1.2bn | ¥2.1bn |
| Operating cash flow | −¥1.6bn | −¥1.8bn | −¥1.3bn | −¥1.3bn | −¥940m | −¥727m |
| EPS (basic) | ¥-140.45 | ¥-195.58 | ¥-198.78 | ¥-234.51 | ¥-178.58 | ¥-187.34 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 55 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 99 figures · EDINET |
15 more reports are still being processed.